Preparation method of eriocaulon buergerianum polysaccharide and novel antitumor application of eriocaulon buergerianum polysaccharide
By preparing and purifying the glutinous polysaccharide, the shortcomings of the glutinous polysaccharide in the prior art in lung cancer treatment have been solved, significantly inhibited the proliferation and migration of lung cancer cells, and developed new anti-lung cancer drugs and provided new treatment plans.
Patent Information
- Application Number
- CN202411148805.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-08
AI Technical Summary
Among the prior art, there are few researches on the treatment of lung cancer, and the lack of effective anti-tumor drugs, resulting in poor treatment effect of lung cancer.
By preparing glutinous glutinous polysaccharide, the purified glutinous polysaccharide was obtained by hot water extraction, dialysis, decolorization, protein removal, ion column separation and other methods, and the inhibitory effect on lung cancer cells was verified through experiments, and it was developed as an anti-tumor. drug.
Polysaccharides of Germia significantly inhibits the proliferation, migration and invasion of lung cancer cells, has a good anti-lung cancer effect in the body, and is expected to be developed as a new anti-tumor drug, especially the treatment method for lung cancer.
Smart Images

Figure CN118903183A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically is a preparation method of spatholobiaceae polysaccharide and a new anti-tumor application thereof. Background Art
[0002] Lung cancer is the malignant tumor with the highest mortality rate in my country. Clinically, lung cancer can be generally divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), of which NSCLC accounts for as high as 80-85%. The occurrence of lung cancer is usually related to factors such as smoking and environmental pollution. The main reason for the high mortality rate of lung cancer is that lung cancer is usually in the metastasis stage when it is discovered, and metastasis is the main feature of advanced lung cancer. Studies have shown that lung cancer mainly metastasizes through lymphatic vessels and blood vessels. Metastasis through the lymphatic route usually takes longer to form distant metastases, while spread through blood vessels will form metastases in the early stage of distant metastases. Lung cancer has some priority metastasis sites, such as brain, bones and adrenal glands, and other organs are usually involved in the late stage of the disease. Among different types of lung cancer, there is also a priority metastasis site, such as liver metastasis of SCLC and brain metastasis of adenocarcinoma.
[0003] In my country, Herba Corydalis is used as a traditional Chinese medicine due to its high medicinal value. According to the records of traditional medicine classics such as Compendium of Materia Medica and Supplement to Materia Medica, it has the effects of clearing away heat and wind, clearing the liver and improving eyesight, and diuresis and analgesia. The 2010 edition of the Chinese Pharmacopoeia stipulates that the dried capitulum with flower stems of Herba Corydalis is used as a traditional Chinese medicine Herba Corydalis. Herba Corydalis contains multiple ingredients such as polysaccharides, glycosides, flavonoids and trace elements. Studies have shown that Herba Corydalis extracts have pharmacological activities such as antibacterial, antioxidant, anti-aging, anti-tumor, and neuroprotection.
[0004] Chinese herbal polysaccharides are a class of polysaccharide compounds that are widely found in Chinese herbal medicines. They have a long history and are widely used in traditional Chinese medicine. In recent years, traditional Chinese medicine has begun to play an important role in the treatment of lung cancer and has achieved remarkable results. Chinese herbal polysaccharides are widely used in anti-cancer treatment due to their low toxicity and side effects. They have different degrees of therapeutic effects on inhibiting the proliferation and metastasis of tumor cells and enhancing immunity. Chinese herbal polysaccharides can also promote the growth of intestinal probiotics, repair intestinal mucosa, and play a positive role in the treatment of lung cancer.
[0005] So far, there has been no report on the research of Eriocauli Flos Polysaccharide (EFP) in lung cancer. Therefore, the present invention is expected to further clarify the anti-tumor activity and intrinsic mechanism of Eriocauli Flos Polysaccharide, which is conducive to the development of new uses of Eriocauli Flos Polysaccharide in the treatment of lung cancer. Summary of the invention
[0006] In order to solve the above technical problems, the present invention provides a method for preparing polysaccharide from Codonopsis pilosula and a new anti-tumor application thereof.
[0007] The technical solution of the present invention is as follows:
[0008] The invention provides use of spatholobi polysaccharide in preparing anti-tumor drugs.
[0009] Furthermore, the present invention provides the use of Herba Codonopsis pilosulae polysaccharides in the preparation of anti-lung cancer drugs.
[0010] The present invention has found through experiments that the use is to inhibit lung cancer cells (A549, LLC) through the polysaccharide of Coptis chinensis.
[0011] The present invention determines the molecular weight and monosaccharide components of the separated components of the Herba Corydalis polysaccharides. The Herba Corydalis polysaccharides are heteropolysaccharides mainly composed of glucose.
[0012] The Herba Corydalis polysaccharides are obtained by air-drying and crushing the Herba Corydalis to obtain powder, and then subjecting the powder to hot water extraction, dialysis, decolorization, protein removal, defatting, and ion column separation to obtain a polysaccharide separation component.
[0013] Specifically, the Herba Corydalis polysaccharides are prepared by the following method:
[0014] (1) air-dried and crushed Herba Corydalis powder is extracted with hot water, and the obtained aqueous extract is filtered, centrifuged, concentrated by a rotary evaporator, and concentrated by dialysis to obtain crude polysaccharides;
[0015] (2) decolorizing, deproteinizing and defatting the crude polysaccharide obtained in step (1) to obtain purified crude polysaccharide;
[0016] (3) The crude polysaccharide obtained in step (2) is purified using a DEAE-Sepharose FF ion column, and then concentrated, dialyzed, and freeze-dried to obtain purified polysaccharide.
[0017] Furthermore, the Herba Corydalis polysaccharides are prepared by the following method:
[0018] (1) Fresh Herba Corydalis was air-dried and crushed, dissolved in distilled water, extracted with hot water for 2 h, and the water extract was taken out for filtration and centrifugation. The concentrated extract was concentrated by rotary evaporation, poured into a 500 Da dialysis bag, and after dialysis for several days, the crude polysaccharide was obtained by freeze drying in a freeze dryer;
[0019] (2) The purification of crude polysaccharides goes through three steps: decolorization, protein removal, and defatting. Decolorization: Dissolve the sample with distilled water, treat it with the NaOH-H2O2 method, dialyze it overnight with a 500Da dialysis bag to remove small molecule impurities, and concentrate and freeze-dry it. Protein removal: Dissolve the sample with distilled water, remove the protein with a chloroform-n-butanol mixture, and repeat the Sevag method five times. Finally, centrifuge, collect the supernatant, concentrate and freeze-dry. Defatting: Add petroleum ether solution to the freeze-dried sample after protein removal until the liquid surface covers all the samples. After ultrasonication for 1 hour, discard the upper solution and air-dry the remaining sample;
[0020] (3) Gradual purification of polysaccharides: EFP was isocratically eluted and separated using a large ion column with three concentrations of mobile phase (0 M, 1 M, and 2 M) to obtain several components. The collected components were concentrated separately, dialyzed with 500 Da to remove all NaCl, and then concentrated and freeze-dried to obtain the polysaccharide component of Herba Corydalis.
[0021] Furthermore, in step (1), when hot water is used for extraction, the volume ratio of the Herba Corydalis powder to distilled water is 1:8.
[0022] Furthermore, in step (2), the decolorization is carried out using a NaOH-H2O2 method, wherein the NaOH is 4M, the pH is adjusted to 9-10, and then 30% H2O2 is added, stirred for 1.5 hours, and repeated three times.
[0023] Furthermore, in step (2), the Sevag method is used for protein removal, the volume ratio of chloroform-n-butanol is 4:1, and the volume ratio of the sample solution to the chloroform-n-butanol mixture is 1:1.
[0024] Furthermore, in step (2), petroleum ether solution is used for degreasing, and the solution is added until the liquid surface covers all samples. After ultrasonication for 1 hour, the upper layer of solution is discarded, and the precipitate is air-dried to complete the degreasing.
[0025] Furthermore, in the graded purification step, the optimal conditions for gradient elution of EFP were first determined using a small DEAE-Sepharose FF ion column: sample load (0.2 g), mobile phase (2.0 M NaCl solution), and collection volume (5.0 mL / tube). On this basis, the optimal elution conditions for a large ion column were obtained through adjustments.
[0026] Furthermore, HPLC was used to detect the molecular weight and monosaccharide composition of the separated components of the polysaccharide from Codonopsis pilosula.
[0027] The medicine of the present invention also includes pharmaceutically acceptable carriers, diluents, excipients, etc., and the preparations of the medicine include liquid preparations, granules, tablets, granules, capsules, sustained-release preparations or injections, etc.
[0028] The beneficial effects of the present invention are as follows: The present invention provides a preparation of Coptis chinensis polysaccharide and a new anti-tumor use thereof. Compared with the existing traditional Chinese medicine polysaccharides related to lung cancer treatment, the method extracts Coptis chinensis polysaccharide components and uses them as anti-tumor drugs, which have inhibitory effects on the proliferation, migration and invasion of lung cancer cells (A549, LLC). Animal experimental results show that Coptis chinensis polysaccharide has a good in vivo anti-lung cancer effect and is expected to be developed as a new anti-tumor drug, especially lung cancer. The present invention is conducive to the development of new anti-lung cancer uses of Coptis chinensis polysaccharide and the development of anti-tumor treatment methods combined with traditional treatment methods. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 This is the gradient elution curve of Herba Corydalis polysaccharides.
[0030] Figure 2 The molecular weights of various components of Herba Codonopsis pilosulae polysaccharides determined by HPLC.
[0031] Figure 3 The monosaccharide composition of Herba Codonopsis pilosulae polysaccharides determined by HPLC.
[0032] Figure 4 This is the effect of Herba Codonopsis pilosulae polysaccharides at different concentrations on the activity of A549 cells for 24 hours.
[0033] Figure 5 This is the effect of Herba Codonopsis pilosulae polysaccharides at different concentrations on LLC cell activity for 24 hours.
[0034] Figure 6 The effects of Herba Corydalis polysaccharides on the migration and invasion ability of A549 cells; (AB) Representative images of A549 migrating cells and wound healing rate after Herba Corydalis polysaccharides treatment; (CD) Representative images of A549 invasive cells and the number of invasive cells after Herba Corydalis polysaccharides treatment.
[0035] Figure 7 The effects of Herba Corydalis polysaccharides on LLC cell migration and invasion ability; (A) Representative images of LLC migrating and invading cells after Herba Corydalis polysaccharides treatment; (BC) The number of LLC migrating and invading cells after Herba Corydalis polysaccharides treatment.
[0036] Figure 8 This is the effect of Herba Codonopsis pilosulae polysaccharides on the expression of LLC cell-related genes.
[0037] Fig. 9 The weight changes of mice on the last day of the experiment.
[0038] Fig.10 is the number of lung nodules in mice.
[0039] Fig.11 This is the effect of Herba Codonopsis pilosulae polysaccharides on the expression of lung tissue-related genes. DETAILED DESCRIPTION
[0040] Experimental Example 1: Preparation of Herba Codonopsis pilosulae polysaccharides
[0041] The collected fresh Herba Corydalis was air-dried and crushed, 1 kg of the pre-treated Herba Corydalis raw material was taken and dissolved in 8 L of distilled water, and hot water was extracted for 2 h, and the water extract was taken out for suction filtration and centrifugation. The polysaccharide concentrated water extract was concentrated using a rotary evaporator, and poured into a 500 Da dialysis bag. After dialysis for several days, it was concentrated again, and the concentrated solution was freeze-dried in a freeze dryer to obtain crude polysaccharides;
[0042] Purification of crude polysaccharides:
[0043] (1) Decolorization
[0044] After dissolving the above sample in 300 mL of distilled water, add 4 M NaOH to adjust the pH to 9-10 (about 2 ml of 4 M NaOH), gradually add 10 ml of 30% H2O2, stir magnetically for 1.5 h, add NaOH again, repeat the above operation three times, and finally use a 500 Da dialysis bag, dialyze overnight, concentrate and freeze-dry;
[0045] (2) Protein removal
[0046] Prepare 1L of chloroform-n-butanol mixture (volume ratio of 4:1), dissolve the sample in 200ml of distilled water, add chloroform-n-butanol mixture in a volume ratio of 1:1, shake thoroughly, centrifuge, pour out the supernatant, pour the chloroform layer and the turbid layer containing protein into a separatory funnel, separate, discard the chloroform and protein, mix the upper solution with the previous supernatant, continue to remove protein using the Sevag method, repeat 5 times. Finally, centrifuge, collect the supernatant, concentrate, dialyze, concentrate, and freeze-dry;
[0047] (3) Degreasing
[0048] To the above freeze-dried samples, petroleum ether solution was added until the liquid surface covered all the samples, and after stirring and mixing, ultrasonication was performed for 1 h. The upper petroleum ether solution was poured out and discarded, and the lower precipitate was placed in a fume hood to air-dry the residual petroleum ether solution (it is expected to be completely air-dried in 2-3 h) to obtain an air-dried sample.
[0049] Polysaccharide fractionation and purification
[0050] (1) Determination of elution conditions for DEAE-Sepharose FF ion column purification
[0051] The small DEAE-Sepharose FF ion column was cleaned with 2M NaOH, and the elution volume was about 50ml; then the column was balanced with 50ml distilled water until the column eluted to neutrality, 0.1g-0.5g of the purified polysaccharide sample was dissolved in 5ml distilled water and loaded, eluted with 30ml distilled water and the water washing fractions were collected, and then 2M NaCl solution was passed through a gradient mixer to collect 5ml of gradient elution fractions per tube, and then 30ml of 2M NaCl elution fractions were collected, and finally 30ml of 4M NaCl elution fractions were collected, and the collected fractions were detected by phenol-sulfuric acid method, and a gradient elution curve was prepared ( Figure 1 ) to determine the elution conditions where the polysaccharide components are mainly concentrated.
[0052] (2) Elution with large anion exchange column
[0053] Under the ion column conditions of (1), isocratic elution is performed using a large anion exchange column to achieve the purpose of enriching the main components. Through the above steps, several components can be separated from the purified polysaccharide sample. The collected components are concentrated separately, dialyzed with 500Da to remove all NaCl, and then concentrated to a suitable volume and freeze-dried.
[0054] HPLC was used to detect the molecular weight and monosaccharide composition of the isolated components of Coptis chinensis polysaccharide. The results are as follows Figure 2 and Figure 3 As shown, the components and their molecular weights are: GJC (2.67 kDa), GJC-DP (2.82 kDa), GJC-DP-DC (3.07 kDa), GJC-W (5.56 kDa), GJC-1M (4.74 kDa), and GJC-2M (5.11 kDa). The monosaccharide composition information of each separated component is shown in Table 1. As the degree of separation and purification increases, the molecular weight gradually increases.
[0055] Table 1 Chemical composition analysis of Herba Codonopsis pilosulae polysaccharides
[0056]
[0057] Note: Yield, Total Sugar, Pr, Reducing Sugar, Glucan, MW, monosaccharides (molar ratio), Man, GlcN, Rha, GlcNAc, GlcA, GalA, Glc, Gal, Xyl represent yield, total sugar, protein, reducing sugar, glucan, molecular weight, monosaccharide molar ratio, mannose, glucosamine, rhamnose, N-acetylglucosamine, glucuronic acid, galacturonic acid, glucose, galactose, xylose, fucose, respectively.
[0058] Experimental Example 2: In vitro anti-lung cancer activity of Herba Corydalis polysaccharides
[0059] (1) Polysaccharides from Codonopsis pilosula inhibit the activity and proliferation of lung cancer cells (A549, LLC)
[0060] Five concentrations of Herba Corydalis polysaccharides were set at 0.25, 0.5, 1, 2, and 4 mg / ml. After treating lung cancer cells for 24 hours, the cell activity of A549 and LLC was detected using the MTT method. The results are shown in Figure 4 and Figure 5 As shown, polysaccharides from Rhizoma Corydalis have an inhibitory effect on the activity of A549 and LLC cells in a concentration-dependent manner.
[0061] (2) Polysaccharides from Codonopsis pilosula inhibit the migration and invasion of lung cancer cells
[0062] The concentration of polysaccharide from Codonopsis pilosula was set at 1 mg / ml. The cell migration activity of A549 was determined by cell scratch assay, and the cell invasion ability was determined by Transwell cell invasion assay. The results are shown in Figure 6 As shown:
[0063] Compared with the control group, the migration activity of A549 cells was significantly reduced under the action of all components (P < 0.01), especially the two components with high purification purity, GJC-W and GJC-2M (P < 0.001); all components could significantly inhibit the invasion of A549 cells, especially GJC-W (P < 0.001).
[0064] The concentration of spatholobiaceae polysaccharide was set at 1 mg / ml. The Transwell migration assay was used to verify the migration activity of semi-adherent LLC cells. The Transwell cell invasion assay was used to determine the cell invasion ability. The results are shown in Figure 7 As shown:
[0065] Compared with the control group, all components could significantly reduce the migration activity of LLC (P<0.001); each component could significantly inhibit the invasion of LLC cells; combining the results of migration and invasion, GJC-W had the best effect.
[0066] (3) Effect of Herba Codonopsis pilosulae polysaccharides on the expression of tumor-related genes in LLC cells
[0067] The target proteins of the active ingredients of Herba Corydalis were obtained in TCMSP, and the lung cancer targets were retrieved in GeneCards, OMIM and DisGeNET databases, so as to construct a Venn diagram to obtain the common targets of Herba Corydalis and lung cancer. Five candidate targets were obtained, namely PTGS2, PPARG, CASP3, BCL2 and CCND1. PPARG is a ligand-activated transcription factor belonging to the peroxisome proliferator-activated receptor (PPARs) family, which is widely expressed in many cells and tissues of the human body and is a potential therapeutic target for various malignant tumors [Peters JM, Shah YM, Gonzalez F J. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nature Reviews. Cancer, 2012, 12(3): 181-195.]. CASP3, or Caspase-3, is a key enzyme in the apoptosis pathway and is crucial in tumorigenesis and cancer progression [Elkhalifa AEO, Banu H, Khan MI, et al. Integrated Network Pharmacology, Molecular Docking, Molecular Simulation, and In Vitro Validation Revealed the Bioactive Components in Soy-Fermented Food Products and the Underlying Mechanistic Pathways in Lung Cancer. Nutrients, 2023, 15(18): 3949.]. BCL2 is the most characteristic anti-apoptotic protein in the BCL2 protein family. Anti-apoptotic proteins targeting the BCL2 family can promote cell apoptosis to overcome tumor chemotherapy resistance [Qian S, Wei Z, Yang W, et al. The role of BCL-2family proteins in regulating apoptosis and cancer therapy. Frontiers in Oncology, 2022, 12: 985363.].CCND 1 is an oncogene that is closely related to the occurrence and development of lung cancer [George J, Lim JS, Jang SJ, Cun Y, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015 Aug 6; 524(7563): 47-53.]. qPCR was used to detect the expression of 5 candidate genes in LLC cells treated with Glechoma longituba polysaccharide, and the results are as follows. Figure 8 As shown:
[0068] qPCR results showed that the expression of PPARG and PTGS2 was significantly upregulated, while the expression of CASP3, BCL2, and CCND1 was significantly downregulated, indicating that R. scoparia polysaccharide inhibited the growth of LLC cells.
[0069] Experimental Example 3: In vivo anti-lung cancer activity of Herba Corydalis polysaccharides
[0070] (1) Construction of Lewis lung cancer mouse model
[0071] C57BL / 6J mice (male, 4 weeks, 18g) were fed adaptively for 1 week before the experiment. Mice in good condition and with similar body weight were randomly divided into 3 groups (n=5): including the normal group NC (equal volume of normal saline), the model group MC (equal volume of normal saline), and the group treated with 100 mg / kg / dose of G. juncea (GJC). Except for the normal group, the mice in the other groups were injected with LLC cell suspension (inoculation amount of 1*10^6 / mouse) through the tail vein to construct a mouse lung cancer metastasis model. During the experiment, mice were gavaged every day. The normal group and the model group were gavaged with normal saline once a day for 5 weeks. The body weight was recorded before the last administration. The results are shown in the figure. Fig. 9 As shown, there was no difference in body weight among the three groups. After 24 hours, the mice were euthanized and dissected to obtain their lungs.
[0072] (2) Polysaccharides from Codonopsis pilosula inhibit the growth and metastasis of lung cancer tumors
[0073] After 35 days, all mice had a certain degree of lung tumor nodules in their lungs, indicating that Lewis lung cancer mouse modeling was successful. Fig.10 As shown, compared with MC, the number of metastatic lung nodules on the lung cell surface of each mouse in the group treated with Coptis chinensis was significantly reduced, and its effect of inhibiting tumor metastasis and growth was significant.
[0074] (3) Effects of Herba Codonopsis pilosulae polysaccharides on tumor gene expression levels
[0075] The expression of five candidate genes in lung tissue was determined by qPCR. Fig.11As shown in the data, compared with the model group, the expression of PPARG in the lung tissue of the Herba Corydalis treated group was significantly upregulated (P < 0.001), while the expression of CASP3 was significantly downregulated (P < 0.001), which was consistent with the results of in vitro experiments. It is speculated that these genes may be closely related to their anti-lung cancer effects.
[0076] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principle of the present invention are included in the protection scope of the present invention.
Claims
1. Use of Herba Codonopsis pilosulae polysaccharides in the preparation of anti-tumor drugs.
2. The use according to claim 1, characterized in that Use of Herba Corydalis polysaccharides in the preparation of anti-lung cancer drugs.
3. The use according to claim 1 or 2, characterized in that The use is to inhibit lung cancer cells (A549, LLC) through the polysaccharide of Coptis chinensis.
4. The use according to claim 1 or 2, characterized in that The spatholobiaceae polysaccharide is a heteropolysaccharide mainly composed of glucose.
5. The use according to claim 1 or 2, characterized in that The Herba Corydalis polysaccharides are prepared by the following method: (1) air-dried and crushed Herba Corydalis powder is extracted with hot water, and the obtained aqueous extract is filtered, centrifuged, concentrated by a rotary evaporator, and concentrated by dialysis to obtain crude polysaccharides; (2) decolorizing, deproteinizing and defatting the crude polysaccharide obtained in step (1) to obtain purified crude polysaccharide; (3) The crude polysaccharide obtained in step (2) is purified using a DEAE-Sepharose FF ion column, and then concentrated, dialyzed, and freeze-dried to obtain purified polysaccharide.
6. The use according to claim 5, characterized in that In step (1), when hot water is used for extraction, the volume ratio of the Herba Codonopsis pilosulae powder to distilled water is 1:
8.
7. The use according to claim 5, characterized in that In step (2), the decolorization is carried out by using a NaOH-H2O2 method, wherein the NaOH is 4M, the pH is adjusted to 9-10, and then 30% H2O2 is added, stirred for 1.5 hours, and repeated three times.
8. The use according to claim 5, characterized in that In step (2), the Sevag method is used for protein removal, the volume ratio of chloroform-n-butanol is 4:1, and the volume ratio of the sample solution to the chloroform-n-butanol mixture is 1:
1.
9. The use according to claim 5, characterized in that In step (2), petroleum ether solution is used for degreasing, and the solution is added until the liquid surface covers all samples. After ultrasonication for 1 hour, the upper solution is discarded, and the precipitate is air-dried to complete the degreasing.
10. The use according to claim 1 or 2, characterized in that The medicine also includes pharmaceutically acceptable carriers, diluents, and excipients, and the preparations of the medicine include liquid preparations, granules, tablets, granules, capsules, sustained-release preparations, or injections.
